8-K current report · filed Aug 10, 2026

Apogee Therapeutics, Inc. (APGE) 8-K Current Report: August 10, 2026

Item EX-99.1Item 2.02APGE overview

Short answer

Apogee Therapeutics, Inc. (APGE) filed an 8-K current report with the SEC on August 10, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Apogee announced financial results for the quarter ended June 30, 2026.

Apogee Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Apogee announced financial results for the quarter ended June 30, 2026
  • Business update and detailed quarterly results available in Exhibit 99.1 earnings press release
  • Investor focus: pipeline progress, cash position and development spending disclosed in the accompanying release

Item EX-99.1 · Exhibit EX-99.1

  • Pending AbbVie acquisition at $135.11 per share cash, valuing Apogee’s equity at approximately $10.9 billion
  • Transaction expected to close in Q3 2026, subject to shareholder and regulatory approvals
  • Zumilokibart Phase 2 achieved 65.9% EASI-75 response and 41.9% placebo-adjusted response, supporting Phase 3 launch this year
  • Cash, marketable securities and long-term securities reached $1.3 billion at June 30, 2026, versus $621.2 million one year earlier
  • Q2 net loss widened to $85.9 million from $66.1 million as R&D increased to $67.3 million and G&A to $24.3 million

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Apogee Therapeutics, Inc. 8-K filings

Get the next APGE 8-K as it lands

Follow APGE for push alerts, or ask the research agent what this filing means.